Evidence map›Paper›PMID 27049304›Full record

ArticleEuropean journal of human genetics : EJHG2016

A novel kinase mutation in VEGFR-1 predisposes its αC-helix/activation loop towards allosteric activation: Atomic insights from protein simulation.

Taseem A Mokhdomi, Shoiab Bukhari, Naveed Anjum Chikan, Asif Amin, Asrar H Wafai, Sajad H Wani, Nisar A Chowdri, Raies A Qadri

Open access · bronzeAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Therapeutic advances of targeting receptor tyrosine kinases in cancer.Signal transduction and targeted therapy · 2024
    Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Taseem A MokhdomiDepartment of Biotechnology, University of Kashmir, Srinagar (J and K), India.ORCID 0000-0001-8903-9662
Shoiab BukhariDepartment of Biotechnology, University of Kashmir, Srinagar (J and K), India.
Naveed Anjum ChikanDepartment of Biotechnology, University of Kashmir, Srinagar (J and K), India.ORCID 0000-0002-5977-0531
Asif AminDepartment of Biotechnology, University of Kashmir, Srinagar (J and K), India.
Asrar H WafaiDepartment of Biotechnology, University of Kashmir, Srinagar (J and K), India.
Sajad H WaniDepartment of Biotechnology, University of Kashmir, Srinagar (J and K), India.
Nisar A ChowdriDepartment of General Surgery, Sher-i-Kashmir Institute of Medical Sciences, Srinagar (J and K), India.
Raies A QadriDepartment of Biotechnology, University of Kashmir, Srinagar (J and K), India.
University of Kashmir · INSher-i-Kashmir Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular endothelial growth factor receptor 1 (VEGFR-1) has been implicated in diverse pathologies, including cancers. Although VEGFR-1 is considered as functionally impaired kinase, its decoy characteristics make it an important regulator of VEGFR-mediated signaling, particularly in tumor angiogenesis. VEGFR-1 conveys signaling via its tyrosine kinase (TK) domain whose activation is regulated by phosphorylation of specific tyrosine residues. Thus dysregulation of VEGFR-1 signaling, as reported in most of the cancers, might be a consequence of altered phosphorylation that could be attributed to genotypic variations in its TK domain. Considering the importance of TK domain of VEGFR-1, we carried out its mutational screening in 84 clinically validated and histopathologically confirmed colorectal cancer patients. By means of direct DNA sequencing and SNP analyses, eight novel variations, including one synonymous, two deletion, one missense and four intronic variations, were reported in the TK domain of VEGFR-1. rs730882263:C>G variation specifically reported in colon cancer, representing a single-atomic change (Sulfur to Oxygen) in the predicted (p.Cys1110Ser) protein, was observed as potentially deleterious variation as assessed by multiple single-nucleotide polymorphism prediction servers. Molecular dynamics simulations of VEGFR-1 Wt and (p.Cys1110Ser) variant models revealed major conformational changes in variant protein presumptuously generating an open conformation thereby exposing the activation domain and consequently increasing the probability of phosphorylation events: a condition frequently reported in cancers.

Indexed as

Allosteric SiteMolecular Dynamics SimulationMutation, MissenseAllosteric RegulationColorectal NeoplasmsFemaleGene DeletionHumansMalePhosphorylationPolymorphism, Single NucleotideProtein Conformation, alpha-HelicalProtein Processing, Post-TranslationalVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-1

Identifiers

PMID27049304
PMCPMC4989210
OpenAlexW2334370182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.